Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jan 27, 2026 (9 months ago)

Diclofenac Sodium

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Diclofenac Sodium, Topical Gel, 3%, 100 g tube, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1363-7

Affected NDC 51672-1363-07

Compare with the code on your package — it is the most precise check available.

Drug: Diclofenac Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Diclofenac sodium
NDC 51672-1363
30 mg/g Gel
Topical
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
51672-1363-7
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0342-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Diclofenac recalls

See all
Class II · Moderate risk

Diclofenac Sodium Topical Solution 1.5% w/w

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Terminated Stability / shelf life Preferred Pharmaceuticals, Inc. NDC 68788-7918-01 D-0773-2022

Other recalls by Sun Pharmaceutical Industries INC

All 2026 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026